Compare Ralph Lauren Corp (RL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs Sanofi SA — how do they compare? Ralph Lauren Corp trades at $340.2 (market cap $20.69B), while Sanofi SA trades at $42.7 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 5× Ralph Lauren Corp's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| RL | SNY | |
|---|---|---|
Market Cap | $20.69B | $104.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $52.34 |
52-Week Low | $302.89 | $41.33 |
Enterprise Value | $21.75B | $124.09B |
Dividend Yield | 1.15% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $347.23, down 1.13% on the day, with the stock showing bearish technical signals despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 surpassing the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent corporate developments include a new cancer center partnership in South Korea and ongoing AI investments to enhance customer experience.
The investment outlook remains positive with 66% analyst buy ratings and a $456.50 consensus price target representing 31% upside potential. However, the stock faces near-term technical pressure with bearish moving averages and faces execution risks in maintaining luxury brand positioning amid economic uncertainty. Strong profitability metrics including 37.54% ROE and improving cash flow generation support the long-term growth thesis.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
